Dexcom opens Ireland manufacturing facility, reaches 500 hires
Dexcom has officially opened its new manufacturing facility in Athenry, County Galway, Ireland, which began commercial production in October. This facility, representing a €300 million investment, is Dexcom's first manufacturing presence in the EMEA region. The company has already hired nearly 500 employees towards its goal of over 1,000 jobs, with remaining roles to be filled as production scales to meet demand for continuous glucose monitoring devices.
Under a trading plan, Dexcom (DXCM) officer Michael Jon Brown sold 1,700 shares at $83.46 each.
Dexcom (DXCM) officer Michael Jon Brown sold 1,700 shares of common stock at $83.46 per share on November 16, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, Brown's holdings amount to 95,034 shares, which include 69,053 unvested restricted stock units. This transaction was reported in an SEC Form 4 filing.
Kevin Chin Purchases 287,000 VivoPower Shares via Arowana Global Impact on November 17, 2026
Kevin Chin, Chairman and CEO of VivoPower PLC, acquired 287,000 Class A Ordinary Shares at $1.93 each on November 17, 2026, through Arowana Global Impact Pty Ltd. This transaction, revealed in a Form 4 filed on November 18, 2026, significantly increases his beneficial ownership in the company. Following this purchase, Chin's total indirect holdings via Arowana Global Impact Pty Ltd amount to 3,363,446 Class A Ordinary Shares, in addition to other shares held through various entities.
DexCom (NASDAQ:DXCM): Strong Growth Fundamentals Meet a Constructive Technical Setup
DexCom (NASDAQ:DXCM) exhibits strong growth fundamentals with a constructive technical setup, making it an attractive prospect for investors. The company scores highly in profitability and financial health, with robust EPS and revenue growth, despite a weaker valuation score typical for growth stocks. Technically, DXCM shows consolidation with reduced volatility, suggesting a potential breakout opportunity despite a mixed overall technical report and current market risks.
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms
DexCom anticipates a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, primarily targeting Type 2 diabetes patients. The company expects a decision from CMS before year-end and plans for significant long-term revenue growth and operating margin expansion through 2030. DexCom is also focusing on international expansion, launching new sensors like the G8, and committing to returning at least half of its free cash flow to shareholders through buybacks.
Rank One Computing Announces CFO Cody Barnes' Resignation and Interim CFO Appointment Effective November 16, 2026
Rank One Computing Corporation (NASDAQ:ROC) announced the resignation of CFO Cody Barnes, effective November 16, 2026, due to personal reasons. J. Blake Moore, previously COO, has been appointed as interim CFO and will continue in both roles. Barnes will remain with the company in a non-executive capacity until March 5, 2027, to facilitate a smooth transition.
Dexcom, Inc. Data Breach
Federman & Sherwood is investigating a data breach at Dexcom, Inc. where an unauthorized third party accessed employee accounts via social engineering to download files containing personal information such as names, Social Security numbers, dates of birth, and government identification. Dexcom determined the incident on November 2, 2026, and is offering affected individuals two years of complimentary identity monitoring.
Here's How Much $1000 Invested In DexCom 10 Years Ago Would Be Worth Today
DexCom (NASDAQ: DXCM) has shown strong market outperformance over the past decade, yielding an average annual return of 16.67%. An initial investment of $1000 in DXCM stock ten years ago would now be valued at $4,484.29, illustrating the significant impact of compounded returns. The company currently holds a market capitalization of $30.44 billion.
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Senseonics and Beta Bionics have commercially launched the integration of Eversense 365, a year-long implantable continuous glucose monitor, with the iLet Bionic Pancreas for automated insulin delivery. This system autonomously determines insulin doses without requiring carbohydrate counting, aiming to simplify diabetes management. The companies also plan future integration with Beta Bionics' Mint tubeless patch pump to broaden insulin delivery options.
Dexcom Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach at Dexcom, Inc., a medical device company specializing in continuous glucose monitoring systems. The breach, discovered on November 2, 2026, involved unauthorized access to employee accounts through social engineering, potentially exposing sensitive consumer information such as names, Social Security numbers, dates of birth, government identification, addresses, and health information. Individuals affected by the breach may be entitled to compensation and are encouraged to submit a claim to the law firm.
Dexcom Data Breach Exposes Social Security and Protected Health Data
Dexcom Inc., a medical device company, disclosed a data breach discovered on November 2, 2026. An unauthorized third party accessed and downloaded files containing names, Social Security numbers, dates of birth, government identification, addresses, and protected health information through compromised employee accounts. Dexcom is offering two years of identity monitoring services through Kroll to affected individuals and encourages vigilance against fraud.
Form 144 DEXCOM INC For: 16 November By Investing.com
This article reports on a Form 144 filing for Dexcom Inc. (DXCM) on November 16. Form 144 filings typically indicate an insider's intent to sell restricted or controlled securities. The article provides the title and date of the filing, along with the company's stock symbol and a link to view comments.
Form 144 DEXCOM INC For: 16 November By Investing.com
This article from Investing.com announces the filing of Form 144 for DEXCOM INC on November 16. It is a brief, unelaborated notice indicating a company filing related to restricted securities.
Form 144 DEXCOM INC For: 16 November By Investing.com
Investing.com reports on Form 144 filing for DEXCOM INC, dated November 16. This filing is a regulatory document submitted to the U.S. Securities and Exchange Commission, indicating the intent to sell restricted or controlled securities. The article provides minimal detail beyond the existence of the filing, focusing on the company and the date.
Tandem Mobi sees FDA clearance for tubeless AID system
Tandem Diabetes Care has received FDA clearance for its Tandem Mobi system, a tubeless automated insulin delivery device approved for up to seven days of wear. This new system offers users the flexibility to choose between tubeless and tubed insulin infusion options, making it unique in the market. The company plans a U.S. commercial launch in 2027, with tubeless infusion sets and cartridges available via pharmacy benefits.
DexCom director Nicholas Augustinos sells $679,768 in stock By Investing.com
DexCom director Nicholas Augustinos sold shares worth $679,768 in mid-September 2026 through a pre-arranged trading plan. Despite the sales, DexCom's stock has surged over 35% in the past six months and is considered undervalued by InvestingPro analysis. The company recently reported strong third-quarter results and raised its annual outlook.
DexCom director Nicholas Augustinos sells $679,768 in stock
DexCom director Nicholas Augustinos sold shares worth $679,768 in mid-September 2026 through a pre-arranged trading plan. The sales occurred as DexCom shares have seen over 35% growth in the past six months and were deemed undervalued by InvestingPro analysis. This follows Dexcom's strong third-quarter results and raised outlook for the year.
Form 4 DexCom Inc: Nicholas Augustinos (Director) For: 14 September By Investing.com
This article reports on a Form 4 filing for DexCom Inc, indicating insider transaction activity by Nicholas Augustinos, a Director, on September 14th. Form 4 filings are regulatory documents detailing changes in the ownership of company stock by insiders such as officers, directors, and significant shareholders. The brief piece includes the stock symbol DXCM and notes a 2.38% increase for the company.
Form 4 DexCom Inc: Nicholas Augustinos (Director) For: 14 September By Investing.com
This article reports on a Form 4 filing for DexCom Inc, indicating that Nicholas Augustinos, a director, made a transaction on September 14th. The brief announcement provides the stock symbol DXCM and notes a 2.38% increase.
Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 September
This article reports on a Form 4 filing for DexCom Inc, specifically detailing an insider transaction involving Michael Jon Brown, the EVP Chief Legal Compliance Officer. The filing is dated September 15th, indicating a recent regulatory disclosure related to the company.
Dexcom evp Michael Brown sells $142,868 in company shares By Investing.com
Michael Jon Brown, EVP and Chief Legal Compliance Officer at Dexcom Inc. (NASDAQ:DXCM), sold 1,700 shares of company stock for $142,868 on September 15, 2026, through a pre-arranged trading plan. This sale occurred after Dexcom shares gained approximately 35% in six months, with InvestingPro analysis suggesting the stock is undervalued despite strong financial health. Brown still holds 99,885 shares, including unvested restricted stock units.
Form 4 DexCom Inc: Nicholas Augustinos (Director) For: 14 September By Investing.com
This article reports on a Form 4 filing for DexCom Inc, indicating an insider transaction involving Nicholas Augustinos, a Director, on September 14. The specific details of the transaction are not provided within the article's text, but the filing itself would contain information about stock acquisitions or dispositions by the insider. The article also includes various market data and other news from Investing.com.
Dexcom evp Michael Brown sells $142,868 in company shares By Investing.com
Michael Jon Brown, Executive Vice President and Chief Legal Compliance Officer at Dexcom Inc. (NASDAQ:DXCM), sold 1,700 shares of the company's common stock for $142,868 on September 15, 2026, as part of a pre-arranged trading plan. This sale occurred while Dexcom shares gained 35% over six months and are considered undervalued by InvestingPro. Following the transaction, Brown directly holds 99,885 shares, including unvested restricted stock units.
Tandem Diabetes Care, Inc. (TNDM) stock price, news, quote and history
Tandem Diabetes Care, Inc. (TNDM) is a medical device company specializing in technology solutions for people with diabetes, including insulin delivery systems like the t:slim X2 and Tandem Mobi pumps. The article provides a comprehensive overview of TNDM's stock performance, key financial metrics, recent news, and analyst insights. As of November 16, the stock closed at $18.48, experiencing a decline, while analysts have an average target price of $26.90.
Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
Arrive AI reported a significant fivefold revenue increase in Q3 2026, reaching $39,700, primarily driven by an expanded deployment at Hancock Regional Hospital. The company also announced the availability of its AP3 Plus technology, new partnerships in manufacturing, pharmacy, and drone delivery, and strategic investments to support its autonomous logistics infrastructure. Despite early-stage revenue, Arrive AI is focusing on converting these deployments and partnerships into recurring revenue while streamlining its cost structure.
Tandem Diabetes Care Receives FDA Clearance for Tandem Mobi
Tandem Diabetes Care announced that it received FDA 510(k) clearance for Tandem Mobi, described as the world's first and only tubeless automated insulin delivery system offering up to 7 days of wear. This system provides users with both tubed and tubeless infusion options, simplifying diabetes management with less frequent site changes and integrating Control-IQ+ advanced hybrid closed-loop technology. While analysts have given TNDM a Buy rating with a $40.00 price target, TipRanks' AI Analyst, Spark, rates TNDM as Neutral due to weaker financial quality despite improving margins.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom (DXCM) is positioned for growth due to the potential of the continuous glucose monitoring (CGM) market, strong performance in 2026, and international expansion. Key drivers include the adoption of its G7 15 Day System, manufacturing efficiencies, a European direct distribution strategy, and Smart Basal technology. However, risks like PBM formulary changes, initial margin pressure from the Ireland facility ramp-up, and rising investment requirements could temper operating leverage.
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
Tandem Diabetes Care has received Health Canada approval for several significant updates to its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology. These approvals include compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor and expanded indications for use in individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. These advancements are expected to be available in Canada in the second quarter of 2027, broadening access to innovative diabetes management technology.
CNSY - Cerenome Inc. stock news, filings & ratings | Quantisnow
Cerenome Inc. (CNSY) is a CNS oncology company listed on NASDAQ, specializing in precision diagnostics, targeted therapeutics, and AI for central nervous system cancers. The company's stock recently saw a significant jump (+46.65%) and has been active with news including a new Chief Business Officer appointment, an in-network agreement with Aetna for its CNSide® Diagnostics platform, and an upcoming conference call to discuss clinical data and Q3 2026 financial results. Financially, Cerenome reported $4.20M in revenue for the last twelve months and a net loss of $26.09M.
Tandem recalls Mobi insulin pump, reports 230 adverse events
Tandem Diabetes Care has issued a correction for over 80,000 Mobi insulin pumps due to a false occlusion alarm that can interrupt insulin delivery. The problem, caused by increased friction in the drive module, has led to 230 reported adverse events requiring medical intervention or hospitalization, though no deaths. Tandem advises users to respond to alarms, have a backup insulin delivery method, and contact customer support if alarms persist.
iRhythm Technologies CEO Joins Align Technology’s Board of Directors
Align Technology has appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors, replacing the retiring Andrea Saia. Blackford brings extensive experience in global healthcare, medical technology, and digital innovation from his roles at iRhythm Technologies, Dexcom, NuVasive Inc., and Zimmer Holdings. Align Technology credits Saia for her significant contributions to the company's growth and strategic oversight during her 13-year tenure.
Guardant Health adds five epigenomic cancer-testing tools
Guardant Health has expanded its Guardant360 Liquid blood test with five new epigenomic applications designed to improve breast and lung cancer treatment selection. These additions use the company's InfinityAI platform to combine genomic and epigenomic signals, aiming to inform therapy choices when conventional mutation markers are insufficient. The company reported $231.3 million in third-quarter revenue, with oncology test volume up 58 percent year-over-year.
Tandem Diabetes Care, Inc. (TNDM) stock price, news, quote and history
Tandem Diabetes Care, Inc. (TNDM) stock closed at $17.51, down 6.71% on November 12th, 2026. The company, which specializes in technology solutions for diabetes management, has a market cap of $1.222 billion and reported a negative profit margin of -2.50% in Q3 FY26. Analysts currently have an average 1-year target estimate of $26.90 for the stock.
Spectral AI Q3FY26 Results: Sales miss estimate, EPS beats consensus
Spectral AI reported a significant revenue miss in Q3 FY26, with sales declining 24.7% year-over-year to $2.856 million, falling short of analyst estimates by 46.37%. Despite this, the company's EPS of $(0.11) beat the consensus estimate of $(0.14) by 15.38%, attributed to tighter expense management. The medical diagnostics firm also lowered its full-year 2026 revenue guidance but secured access to $90 million in non-dilutive BARDA funding and remains on track for its first U.S. commercial placement of the DeepView AI System by year-end 2026.
Tax withholding, not a sale: Dexcom (DXCM) EVP Brown has 1,451 shares withheld at $79.41 each.
Dexcom Inc.'s EVP, Michael Jon Brown, had 1,451 common shares withheld by the company on November 8, 2026, at $79.41 per share. This action was taken to cover tax-withholding obligations related to the net settlement of restricted stock units and does not represent a sale by Brown. After this transaction, Brown's direct holdings amount to 96,734 shares, which include 69,053 unvested restricted stock units with various vesting schedules.
Tax withholding, not a sale: Dexcom (DXCM) retains 1,451 shares from its chief people officer.
Dexcom (DXCM) reported that 1,451 shares were withheld from Sadie Stern, its EVP Chief People & Culture Officer, on November 8, 2026. This withholding, valued at $79.41 per share, was to cover tax obligations related to the net settlement of restricted stock units and does not constitute a sale. Following this transaction, Stern's direct holdings stood at 119,462 shares, including 69,053 unvested restricted stock units.
Not a sale: Dexcom (DXCM) withholds 1,451 shares from CEO Jacob Steven Leach for taxes.
Dexcom (DXCM) withheld 1,451 shares from CEO Jacob Steven Leach on November 8, 2026, to cover tax obligations related to the net settlement of restricted stock units. This action was explicitly noted as not a sale by Leach. After this transaction, Leach's direct holdings totaled 417,457 shares, including unvested restricted stock units, and an additional 47,296 shares were held indirectly through a family trust.
The 1,451 shares withheld from Dexcom (DXCM)'s CFO for taxes were not sold.
Dexcom, Inc. (DXCM) reported that its EVP, COO & CFO, Jereme M. Sylvain, had 1,451 common shares withheld on November 8, 2026, to cover tax obligations related to the net settlement of restricted stock units. This action was explicitly noted as not a sale by the reporting person. Following this transaction, Sylvain's direct holdings in the company stood at 145,377 shares, including 84,244 unvested restricted stock units.
Senseonics Holdings Q3 revenue up 140% to USD 19.6M
Senseonics Holdings, Inc. announced its third-quarter 2026 financial results, reporting a 140% year-over-year revenue increase to $19.6 million, driven by strong U.S. performance of Eversense 365. The company also raised its full-year 2026 global net revenue guidance to $68 million to $70 million, reflecting continued commercial momentum and expansion of patient access. Senseonics attributes this growth to its commercial strategy, expanded infrastructure, and upcoming product developments.
Senseonics Q3 Results: Sales jump 141.6% to $19.6M, loss narrows
Senseonics Holdings reported a significant 141.64% year-over-year increase in Q3 sales to $19.561 million, surpassing analyst estimates. The company also narrowed its net loss per share and raised its full-year revenue guidance for the third time, now expecting $68-70 million. These positive results were driven by strong sales, improved gross margin to 62%, and strategic partnerships, including one with Beta Bionics and the start of human testing for its Freedom CGM system.
Advancing type 1 diabetes care during pregnancy: a Canadian first
Health Canada has approved the Dexcom G7 Continuous Glucose Monitoring System for use with myLoop, powered by CamAPS FX, making it Canada's only automated insulin delivery system approved for pregnant women with type 1 diabetes. This advancement provides a crucial new option for managing the complexities of diabetes during pregnancy, a period when insulin needs can vary significantly. The approval is supported by the AiDAPT trial, which demonstrated improved glucose control without increased hypoglycemia risk for women using CamAPS FX.
Align Technology, Inc. (ALGN) stock price, news, quote and history
Align Technology, Inc. (ALGN) is a medical instruments and supplies company providing Invisalign clear aligners and iTero intraoral scanners. The article provides a detailed overview of ALGN's stock performance, key financial metrics, earnings trends, and analyst insights. It also includes company details, recent news, and comparative performance against the S&P 500.
What Is Behind The Move In DexCom Stock?
DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, without company-specific news, echoing similar declines in peers Insulet and Tandem Diabetes Care. Tandem's earnings call revealed slower-than-expected pharmacy distribution which could impact 2027 revenue growth, potentially affecting DexCom due to its presence in the same diabetes market. Despite this recent fall, DexCom's shares have returned 34.0% over the past year, significantly outperforming the S&P 500.
He went from washing lab equipment for $10 an hour to leading a $30 billion healthcare company. His advice to Gen Z: Raise your hand
Jake Leach, CEO of Dexcom, rose from a $10-an-hour lab dishwasher to leading a $30 billion healthcare company without ever asking for a promotion. His career path was shaped by hard work, a childhood fascination with engineering, and a personal connection to diabetes through his grandfather. Leach advises young professionals to take initiative, solve big problems, and volunteer for tasks outside their immediate responsibilities to become more valuable leaders.
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care (TNDM) reported a 14% revenue increase in Q3 2026, driven by higher pump shipments and international sales, though it signaled a slower-than-expected shift to pharmacy distribution could impact 2027 revenue growth. The company also announced CEO John Sheridan's retirement at year-end, with Jeannette Bankes taking over. Tandem reiterated its 2026 sales outlook and shared plans for new product launches, including the Mobi Tubeless system and a fully closed-loop system, pending FDA clearance and study completion.
Ashland Inc stock hits 52-week high at 78.26 USD
Ashland Inc. (ASH) stock reached a 52-week high of $78.26, reflecting a 56% increase over the past year and 42% in the last six months. Despite trading at a P/E ratio of 140 and appearing overvalued by InvestingPro data, the company has maintained dividend payments for 56 consecutive years. Ashland also reported mixed fiscal fourth-quarter results, missing earnings expectations but showing strong cash generation and an optimistic outlook for fiscal 2027.
Tandem Diabetes Care names next CEO
Tandem Diabetes Care has announced Jeannette Bankes as its next CEO, effective November 16, succeeding John Sheridan who will retire at year-end. Bankes joins from GE HealthCare where she was CEO of patient care solutions. Sheridan, who led Tandem since 2019, will remain as a consultant after his retirement, having overseen the launch of key technologies like hybrid closed-loop systems and the development of a tubeless insulin pump.
Guardant Health Q3 Results: Adjusted loss narrows 25% YoY to $(0.29)
Guardant Health reported a 36% year-over-year revenue increase to $361 million in Q3, leading to raised full-year 2026 revenue guidance of $1.36-$1.37 billion. The company's adjusted loss per share narrowed by 25.64% to $(0.29), beating analyst estimates. This performance was driven by strong growth in both oncology and the SHIELD screening segment, coupled with improved cost efficiency.
2 profitable stocks on our buy list and 1 we avoid
This article identifies two profitable stocks, MYR Group (MYRG) and DexCom (DXCM), as "buys" due to strong growth prospects and financial health, while recommending "avoiding" Halliburton (HAL) due to challenges in revenue growth and efficiency. It analyzes each company's performance, margins, and valuation, emphasizing that profitability alone does not guarantee long-term success.
Guardant Health (GH) Added Kevin Sayer To Its Board
Guardant Health (NasdaqGS:GH) has appointed digital health veteran Kevin Sayer to its board of directors, following its recognition with the Prix Galien USA Award for its Shield blood test and inclusion in Business Insider’s 2024 list of America’s Most Innovative Businesses. This appointment and the recent accolades are expected to influence investor perception of Guardant Health's role in cancer screening, reinforcing the company's focus on data-driven diagnostics. The strategic move aims to strengthen the company's position in cancer screening and diagnostics, though challenges like managing patent royalties and cash burn remain.